Furmańczyk Agnieszka, Komuda-Leszek Ewa, Durlik Magdalena
Department of Transplantation Medicine and Nephrology Institute of Transplantology, Medical University of Warsaw, Warsaw, Poland.
Ann Transplant. 2009 Oct-Dec;14(4):47-51.
A case of calcineurin inhibitor (CNI)--induced haemolytic uremic syndrome (HUS) after liver transplantation leading to irreversible renal failure is described.
We present case history of 25-years old male after liver transplantation due to cryptogenic cirrhosis with prolonged worsening graft function, who developed HUS. Unsatisfactory graft function was the reason of performing numerous graft biopsies. Features of acute and chronic rejection (CR) of liver were histopathologically confirmed. Vanishing bile duct syndrome as manifestation of CR was stated and immunosuppressive regimen was intensified (tacrolimus placed cyclosporin). High blood levels of tacrolimus were maintained (approximately 20-22 ng/ml) on dose 3 mg twice a day. No clinical effect was observed. Renal failure was improving (serum creatinine was 3.3 mg/dl and eGFR was 24 ml/min/1.73 m(2)). After four months of maintaining high dose of tacrolimus patient was referred to our center in order to estimate indications for liver retransplantation. On admission severe haemolytic anaemia, thrombocytopenia and acute renal failure were detected. Atypical HUS probably related to CNI was diagnosed. Tacrolimus administration was discontinued. Blood and plasma transfusion as well as plasmapheresis were implemented. Haemolysis was limited, but renal function was not improved. Renal biopsy revealed features of irreversible nephropathy in course of thrombotic microangiopathy. Despite previously maintaining high dose of CNI, there were no signs of CNI nephrotoxicity. Patient required haemodialysis. Due to necessity of haemodialysis and worsening function of liver, patient was accepted to liver and kidney transplantation.
High CNI blood concentration in patient after liver transplantation can be atypical cause of HUS and leads to irreversible renal failure.
本文描述了1例肝移植后因钙调神经磷酸酶抑制剂(CNI)诱发溶血性尿毒症综合征(HUS)导致不可逆肾衰竭的病例。
我们报告了1例25岁男性患者的病史,该患者因隐源性肝硬化接受肝移植,移植肝功能长期恶化,并发生了HUS。移植肝功能不佳是多次进行移植肝活检的原因。肝急慢性排斥反应(CR)的特征经组织病理学证实。诊断为消失胆管综合征作为CR的表现,并强化了免疫抑制方案(他克莫司替代环孢素)。每天两次3mg剂量维持他克莫司的高血药浓度(约20 - 22ng/ml)。未观察到临床效果。肾衰竭有所改善(血清肌酐为3.3mg/dl,估算肾小球滤过率为24ml/min/1.73m²)。在维持高剂量他克莫司4个月后,患者被转诊至我院以评估再次肝移植的指征。入院时检测到严重溶血性贫血、血小板减少和急性肾衰竭。诊断为可能与CNI相关的非典型HUS。停用他克莫司。进行了输血、血浆置换。溶血得到控制,但肾功能未改善。肾活检显示血栓性微血管病过程中存在不可逆肾病的特征。尽管之前维持高剂量CNI,但未出现CNI肾毒性迹象。患者需要血液透析。由于需要血液透析且肝功能恶化,患者接受了肝肾联合移植。
肝移植患者血液中高浓度的CNI可能是非典型HUS的病因,并导致不可逆肾衰竭。